


# Supplementary Figure S7

## Anti-PD-(L)1 and/or chemotherapy validation cohort

(covariate adjusted)



**Supplementary Figure S7. Covariate adjusted Kaplan-Meier analysis of the anti-PD-(L)1 and/or chemotherapy (chemo) validation cohort**

**A.** As in **Figure 4B**, except the Kaplan-Meier visualization of the anti-PD-(L)1 and/or chemotherapy (chemo) validation cohort ( $n=1,229$  treatment lines) in each Immunotherapy Response Score (IRS) group was performed using covariate adjustment. **B.** As in **A**, except showing the non-small cell lung cancer (NSCLC) subgroup. Forest plot of hazard ratios is shown as in **Figure 4B**. **C.** As in **A**, except showing the other four tumor type (Other; triple negative breast cancer, esophagogastric, head and neck cancer, and small cell lung cancer) subgroups.